KEAP1 Activator Program
Oncology
Phase 1Active
Key Facts
About Vividion Therapeutics
Vividion Therapeutics is a private, clinical-stage biotech pioneering a novel drug discovery engine that merges chemoproteomics and covalent chemistry to drug challenging disease targets. The company has advanced multiple programs into clinical trials, including a WRN helicase inhibitor for MSI-high cancers and a KEAP1 activator in oncology, demonstrating platform validation. Led by CEO Aleksandra Rizo, M.D., Ph.D., and CSO Matt Patricelli, Ph.D., Vividion is positioned to address the vast unmet need represented by the estimated 90% of disease-causing proteins currently considered undruggable. Its success hinges on translating its unique platform into clinically effective and commercially viable precision medicines.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| Bendamustine Intermediate | AR Life Science | Commercial |